# Gastrointestinal Bleeding â€“ RRT Protocol with Virtua Voorhees Addenda

**Primary Guideline:** 2023 American College of Gastroenterology Clinical Guidelines for Management of Patients with Acute Lower Gastrointestinal Bleeding
**Official Source:** https://journals.lww.com/ajg/fulltext/2023/02000/acg_clinical_guideline__management_of_patients.9.aspx
**Supporting Guidelines:**
- 2021 ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding[25][26]
- 2024 AASLD Practice Guidelines: Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis[41]
- 2024 ACG/SAR Consensus Statement: Role of Imaging for GI Bleeding[53]

## ENHANCED MERMAID FLOWCHART ALGORITHM

~~~mermaid
graph TD
    A["GI Bleeding Recognition<br/>Hematemesis/Melena/Hematochezia"] --> B["Initial Stabilization<br/>ABCs + Risk Assessment"]
    
    B --> C["Hemodynamic Assessment<br/>Glasgow-Blatchford Score"]
    
    C --> D{"Hemodynamically<br/>Stable?"}
    
    D -->|UNSTABLE| E["Aggressive Resuscitation<br/>2 Large IVs + Blood Products"]
    D -->|STABLE| F["Risk Stratification<br/>Oakland Score + Clinical Assessment"]
    
    E --> G["Critical Care<br/>ICU Monitoring"]
    F --> H{"Risk Level<br/>Assessment?"}
    
    G --> I{"Upper vs Lower<br/>GI Source?"}
    H -->|HIGH| J["Inpatient Management<br/>Early Intervention"]
    H -->|LOW| K["Consider Outpatient<br/>vs Observation"]
    
    I -->|UPPER| L["Upper GI Protocol<br/>EGD + PPI"]
    I -->|LOWER| M["Lower GI Protocol<br/>CT-A vs Colonoscopy"]
    I -->|VARICEAL| N["Variceal Protocol<br/>Octreotide + Antibiotics"]
    
    J --> O["Diagnostic Strategy<br/>Based on Presentation"]
    K --> P["Outpatient Follow-up<br/>vs ED Observation"]
    
    L --> Q{"Peptic Ulcer<br/>vs Other?"}
    M --> R{"CT Angiography<br/>Positive?"}
    N --> S["Urgent EGD<br/>+ Endoscopic Therapy"]
    
    O --> T["Colonoscopy vs CTA<br/>Based on Severity"]
    P --> U["Primary Care<br/>+ GI Follow-up"]
    
    Q -->|PUD| V["Endoscopic Therapy<br/>+ High-dose PPI"]
    Q -->|OTHER| W["Targeted Therapy<br/>Based on Etiology"]
    R -->|POSITIVE| X["Urgent IR Embolization<br/>Within 90 Minutes"]
    R -->|NEGATIVE| Y["Colonoscopy<br/>Next Available"]
    
    S --> Z["Hemostasis Assessment<br/>+ Continued Monitoring"]
    T --> AA["Therapeutic Intervention<br/>If Source Identified"]
    
    V --> BB["Post-Endoscopic Care<br/>PPI + Monitoring"]
    W --> BB
    X --> CC["Post-Embolization<br/>Monitoring"]
    Y --> DD["Endoscopic Therapy<br/>If Indicated"]
    Z --> EE{"Bleeding<br/>Controlled?"}
    AA --> DD
    
    BB --> FF["Disposition Planning<br/>Based on Response"]
    CC --> FF
    DD --> FF
    EE -->|YES| GG["ICU Monitoring<br/>72h Octreotide"]
    EE -->|NO| HH["Salvage Therapy<br/>TIPS/Surgery"]
    
    FF --> II["Step-down Care<br/>Medication Optimization"]
    GG --> II
    HH --> JJ["Advanced Interventions<br/>Multidisciplinary Care"]
    
    II --> KK["Discharge Planning<br/>Medication Reconciliation"]
    JJ --> LL["Recovery/Rehabilitation<br/>Specialist Follow-up"]
    KK --> MM["Home with Follow-up<br/>Return Precautions"]
    LL --> MM
    
    style A fill:#ffcccc
    style E fill:#ff6666
    style N fill:#ffaaaa
    style S fill:#ff8888
    style X fill:#ccffcc
    style HH fill:#e6ccff
    style MM fill:#ccffee
~~~

## STREAMLINED DYNAMIC CARD SYSTEM

### Card 0 â€“ GI Bleeding Recognition & Initial Assessment (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©¸ GASTROINTESTINAL BLEEDING RRT        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Recognition criteria (2024 update):  â”‚
â”‚ â€¢ **Hematemesis:** Coffee grounds/bright red vomitâ”‚
â”‚ â€¢ **Melena:** Black, tarry, foul-smelling stoolsâ”‚
â”‚ â€¢ **Hematochezia:** Bright red/maroon blood PRâ”‚
â”‚ â€¢ **Hemodynamic instability** with GI symptomsâ”‚
â”‚                                         â”‚
â”‚ ğŸš¨ ABC priorities (immediate):          â”‚
â”‚ â€¢ **A**irway: Assess for aspiration riskâ”‚
â”‚ â€¢ **B**reathing: O2 to maintain SpO2 >94%â”‚
â”‚ â€¢ **C**irculation: Large bore IV Ã— 2    â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Essential initial labs (STAT):       â”‚
â”‚ â€¢ CBC with differential                 â”‚
â”‚ â€¢ Comprehensive metabolic panel         â”‚
â”‚ â€¢ Coagulation studies (PT/INR, aPTT)    â”‚
â”‚ â€¢ Type and crossmatch (â‰¥4 units)        â”‚
â”‚ â€¢ Lactate, liver enzymes                â”‚
â”‚                                         â”‚
â”‚ [Next: Risk assessment â–¶]              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1 â€“ Hemodynamic Assessment & Risk Stratification (Node C â†’ D)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš–ï¸ HEMODYNAMIC & RISK ASSESSMENT (2024)  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Glasgow-Blatchford Score (0-23)[25]: â”‚
â”‚ â€¢ **BUN elevation:** Adds 2-6 points    â”‚
â”‚ â€¢ **Hemoglobin level:** Age/sex specificâ”‚
â”‚ â€¢ **Systolic BP:** <110 = 2-3 points    â”‚
â”‚ â€¢ **Heart rate:** >100 = 1 point        â”‚
â”‚ â€¢ **Melena:** 1 point                   â”‚
â”‚ â€¢ **Syncope:** 2 points                 â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Hemodynamic stability indicators:    â”‚
â”‚ â€¢ **Stable:** SBP >100, HR <100, no orthostaticsâ”‚
â”‚ â€¢ **Mild instability:** Orthostatic changesâ”‚
â”‚ â€¢ **Severe instability:** SBP <90, HR >120â”‚
â”‚                                         â”‚
â”‚ ğŸ“ˆ Oakland Score (for LGIB)[27][29]:    â”‚
â”‚ â€¢ **Age, sex, previous bleeding history**â”‚
â”‚ â€¢ **Heart rate, SBP, hemoglobin**       â”‚
â”‚ â€¢ **Score â‰¤8:** Safe discharge candidateâ”‚
â”‚ â€¢ **Score >8:** Hospital intervention neededâ”‚
â”‚                                         â”‚
â”‚ â“ Patient hemodynamically stable?      â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ UNSTABLE â†’ Aggressive resuscitation  â”‚
â”‚ ğŸ”˜ STABLE â†’ Risk-based stratification   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ Aggressive Resuscitation Protocol (Node E â†’ G)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ AGGRESSIVE RESUSCITATION (UNSTABLE)  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’§ Immediate fluid resuscitation:       â”‚
â”‚ â€¢ **2 large-bore IVs:** 18G or larger   â”‚
â”‚ â€¢ **Crystalloid bolus:** 500-1000mL NS/LRâ”‚
â”‚ â€¢ **Avoid over-resuscitation:** Target MAP >65â”‚
â”‚                                         â”‚
â”‚ ğŸ©¸ Blood product protocols (2023)[25]:   â”‚
â”‚ â€¢ **Hemoglobin <7 g/dL:** Transfusion thresholdâ”‚
â”‚ â€¢ **Active bleeding:** Consider Hgb <8-9 g/dLâ”‚
â”‚ â€¢ **CAD/elderly:** Threshold Hgb <8 g/dL â”‚
â”‚ â€¢ **Massive bleeding:** 1:1:1 ratio (RBC:FFP:PLT)â”‚
â”‚                                         â”‚
â”‚ ğŸ§ª Laboratory monitoring:               â”‚
â”‚ â€¢ **Q2-4h CBC** during active bleeding  â”‚
â”‚ â€¢ **Coagulation studies** q6h           â”‚
â”‚ â€¢ **Arterial blood gas** if unstable    â”‚
â”‚                                         â”‚
â”‚ ğŸ¥ ICU criteria:                        â”‚
â”‚ â€¢ Glasgow-Blatchford score >12          â”‚
â”‚ â€¢ Ongoing hemodynamic instability       â”‚
â”‚ â€¢ High transfusion requirements         â”‚
â”‚ â€¢ Need for continuous monitoring        â”‚
â”‚                                         â”‚
â”‚ [Next: Critical care management â–¶]     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Risk Assessment]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2B â€“ Risk-Based Management (Node F â†’ H)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¯ RISK-BASED MANAGEMENT STRATEGY       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š High-risk features (any present):    â”‚
â”‚ â€¢ **Glasgow-Blatchford score â‰¥6**       â”‚
â”‚ â€¢ **Oakland score >8** (for LGIB)       â”‚
â”‚ â€¢ **Age >60** with comorbidities        â”‚
â”‚ â€¢ **Anticoagulation use**               â”‚
â”‚ â€¢ **Cirrhosis/portal hypertension**     â”‚
â”‚ â€¢ **Recent hospitalization**            â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Low-risk features (all present):     â”‚
â”‚ â€¢ **Glasgow-Blatchford score 0-1**      â”‚
â”‚ â€¢ **Oakland score â‰¤8**                  â”‚
â”‚ â€¢ **Hemodynamically stable**            â”‚
â”‚ â€¢ **No high-risk medications**          â”‚
â”‚ â€¢ **Minimal bleeding volume**           â”‚
â”‚                                         â”‚
â”‚ â“ Overall risk assessment?             â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ HIGH â†’ Inpatient management required â”‚
â”‚ ğŸ”˜ LOW â†’ Consider outpatient evaluation â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Clinical judgment override:          â”‚
â”‚ â€¢ Scores supplement but don't replace clinical decision-making[46]â”‚
â”‚ â€¢ Consider patient-specific factors     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ Upper GI Bleeding Protocol (Node L â†’ Q)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”º UPPER GI BLEEDING MANAGEMENT (2024)  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Initial pharmacotherapy:             â”‚
â”‚ â€¢ **High-dose PPI:** Pantoprazole 80mg IV bolusâ”‚
â”‚ â€¢ **Then:** 8mg/hr continuous Ã— 72h OR 40mg IV BIDâ”‚
â”‚ â€¢ **Pre-endoscopic therapy** recommended[25]â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Prokinetic agent (if delayed EGD):   â”‚
â”‚ â€¢ **Erythromycin 250mg IV** over 30min  â”‚
â”‚ â€¢ **Give 30-120min before endoscopy**   â”‚
â”‚ â€¢ **Improves visualization** of bleeding sourceâ”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Diagnostic approach:                 â”‚
â”‚ â€¢ **EGD within 24h** (non-urgent)       â”‚
â”‚ â€¢ **EGD <12h** if high-risk features    â”‚
â”‚ â€¢ **Immediate EGD** if hemodynamic instabilityâ”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Endoscopic stigmata assessment:      â”‚
â”‚ â€¢ **Active spurting/oozing:** Treat immediatelyâ”‚
â”‚ â€¢ **Visible vessel:** High rebleed risk â”‚
â”‚ â€¢ **Adherent clot:** Consider therapy   â”‚
â”‚ â€¢ **Flat spot/clean base:** Low risk    â”‚
â”‚                                         â”‚
â”‚ [Next: Peptic ulcer evaluation â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Source Classification]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3B â€“ Variceal Bleeding Protocol (Node N â†’ S)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©¸ VARICEAL BLEEDING PROTOCOL (2024)    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Immediate pharmacotherapy[41]:       â”‚
â”‚ â€¢ **Octreotide 50mcg IV bolus STAT**    â”‚
â”‚ â€¢ **Then 50mcg/hr continuous Ã— 72h**    â”‚
â”‚ â€¢ **Start before endoscopy**            â”‚
â”‚                                         â”‚
â”‚ ğŸ¦  Antibiotic prophylaxis (Class I):    â”‚
â”‚ â€¢ **Ceftriaxone 1g IV daily Ã— 7 days**  â”‚
â”‚ â€¢ **Reduces infection risk by 50%**     â”‚
â”‚ â€¢ **Mortality benefit demonstrated**    â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Additional support:                  â”‚
â”‚ â€¢ **PPI therapy:** Standard dose (not high-dose)â”‚
â”‚ â€¢ **Avoid beta-blockers** during acute bleedingâ”‚
â”‚ â€¢ **Lactulose** if hepatic encephalopathyâ”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Urgent endoscopic therapy:           â”‚
â”‚ â€¢ **EGD within 12h** of presentation    â”‚
â”‚ â€¢ **Endoscopic band ligation** preferredâ”‚
â”‚ â€¢ **Sclerotherapy** if banding not feasibleâ”‚
â”‚                                         â”‚
â”‚ âš ï¸ Hemoglobin targets:                  â”‚
â”‚ â€¢ **Goal 7-9 g/dL** (avoid over-transfusion)â”‚
â”‚ â€¢ **Over-transfusion worsens portal pressure**â”‚
â”‚                                         â”‚
â”‚ [Next: Urgent endoscopy â–¶]             â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Source Classification]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3C â€“ Lower GI Bleeding Protocol (Node M â†’ R)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”» LOWER GI BLEEDING MANAGEMENT (2023)  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“¸ Initial diagnostic approach[27]:     â”‚
â”‚ â€¢ **Hemodynamically stable:** Colonoscopy preferredâ”‚
â”‚ â€¢ **Ongoing severe bleeding:** CT angiography firstâ”‚
â”‚ â€¢ **Shock index >1.0:** Consider CTA    â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š CT Angiography indications[46]:      â”‚
â”‚ â€¢ **Ongoing hemodynamically significant hematochezia**â”‚
â”‚ â€¢ **Unable to stabilize for colonoscopy**â”‚
â”‚ â€¢ **Recurrent bleeding after colonoscopy**â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ CT-A interpretation:                 â”‚
â”‚ â€¢ **Active extravasation:** IR consult <90minâ”‚
â”‚ â€¢ **No extravasation:** Proceed to colonoscopyâ”‚
â”‚ â€¢ **Anatomic abnormalities:** Guide interventionâ”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Colonoscopy approach:                â”‚
â”‚ â€¢ **Non-urgent preferred** (within 24h) â”‚
â”‚ â€¢ **Urgent not shown to improve outcomes**â”‚
â”‚ â€¢ **Adequate prep essential** for visualizationâ”‚
â”‚                                         â”‚
â”‚ [Next: CTA result interpretation â–¶]    â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Source Classification]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Anticoagulation Reversal (Critical)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”„ ANTICOAGULATION REVERSAL (2023)      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ©¸ Warfarin reversal[27]:               â”‚
â”‚ â€¢ **Life-threatening bleeding + INR >2.5:**â”‚
â”‚ â€¢ **4-Factor PCC:** 25-50 units/kg IV   â”‚
â”‚ â€¢ **Vitamin K:** 10mg IV slow push      â”‚
â”‚ â€¢ **Target INR <1.4** within 30min      â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š DOAC reversal:                       â”‚
â”‚ â€¢ **Dabigatran:** Idarucizumab 5g IV    â”‚
â”‚ â€¢ **Apixaban/Rivaroxaban:** Andexanet alfaâ”‚
â”‚ â€¢ **If specific unavailable:** 4-Factor PCCâ”‚
â”‚                                         â”‚
â”‚ ğŸ©¸ Platelet management:                 â”‚
â”‚ â€¢ **Severe LGIB:** Maintain >50,000/Î¼L  â”‚
â”‚ â€¢ **Endoscopic procedures:** >50,000/Î¼L â”‚
â”‚ â€¢ **Baseline >30,000:** Generally adequateâ”‚
â”‚ â€¢ **Don't transfuse for antiplatelet drugs**[30]â”‚
â”‚                                         â”‚
â”‚ ğŸ«€ Cardiac consideration:               â”‚
â”‚ â€¢ **Secondary prevention ASA:** Continue if possible[30]â”‚
â”‚ â€¢ **Recent stents <1 year:** Multidisciplinary approachâ”‚
â”‚ â€¢ **Primary prevention:** Can discontinueâ”‚
â”‚                                         â”‚
â”‚ [Next: Therapeutic interventions â–¶]    â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4B â€“ CT Angiography Positive (Node X â†’ CC)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“¸ CT ANGIOGRAPHY POSITIVE - IR CONSULT â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš¨ Time-critical intervention[46]:      â”‚
â”‚ â€¢ **Goal: IR consult within 90 minutes**â”‚
â”‚ â€¢ **Active extravasation confirms bleeding**â”‚
â”‚ â€¢ **Location guides embolization approach**â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Interventional radiology options[47]:â”‚
â”‚ â€¢ **Superselective embolization:** Preferredâ”‚
â”‚ â€¢ **Success rate:** 89-98% initial hemostasisâ”‚
â”‚ â€¢ **Clinical success:** 70-80% long-termâ”‚
â”‚                                         â”‚
â”‚ ğŸ”§ Embolization materials:              â”‚
â”‚ â€¢ **Coils:** Permanent occlusion        â”‚
â”‚ â€¢ **Gelfoam:** Temporary, reabsorbable  â”‚
â”‚ â€¢ **PVA particles:** Permanent, varied sizesâ”‚
â”‚ â€¢ **Glue:** For complex anatomy         â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Complications (4.6% incidence):      â”‚
â”‚ â€¢ **Bowel infarction:** <5% risk        â”‚
â”‚ â€¢ **Post-embolization syndrome:** Commonâ”‚
â”‚ â€¢ **Rebleeding:** 10-25% within 30 days â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Success predictors:                  â”‚
â”‚ â€¢ **Active bleeding on angiography**    â”‚
â”‚ â€¢ **Superselective catheterization**    â”‚
â”‚ â€¢ **Appropriate embolic agent selection**â”‚
â”‚                                         â”‚
â”‚ [Next: Post-embolization monitoring â–¶] â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: CTA Results]              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4C â€“ Salvage Therapy (Node HH â†’ JJ)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ†˜ SALVAGE THERAPY FOR REFRACTORY BLEEDINGâ”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ©¸ Variceal bleeding salvage:           â”‚
â”‚ â€¢ **TIPS (Transjugular Intrahepatic Portosystemic Shunt)**â”‚
â”‚ â€¢ **Balloon tamponade:** Bridge to definitive therapyâ”‚
â”‚ â€¢ **Self-expandable metal stents:** Alternative to balloonâ”‚
â”‚                                         â”‚
â”‚ ğŸ”§ TIPS indications[41]:                â”‚
â”‚ â€¢ **Failed endoscopic therapy Ã— 2**     â”‚
â”‚ â€¢ **Child-Pugh Class A/B preferred**    â”‚
â”‚ â€¢ **Within 72h of initial bleeding**    â”‚
â”‚ â€¢ **Contraindicated in severe HE**      â”‚
â”‚                                         â”‚
â”‚ ğŸˆ Balloon tamponade (bridge therapy):  â”‚
â”‚ â€¢ **Sengstaken-Blakemore tube**         â”‚
â”‚ â€¢ **Requires intubation for airway protection**â”‚
â”‚ â€¢ **Maximum 24h inflation**             â”‚
â”‚ â€¢ **80-90% immediate hemostasis**       â”‚
â”‚                                         â”‚
â”‚ ğŸ”ª Surgical options (last resort):      â”‚
â”‚ â€¢ **Portocaval shunt surgery**          â”‚
â”‚ â€¢ **Esophageal transection**            â”‚
â”‚ â€¢ **High mortality in emergency setting**â”‚
â”‚                                         â”‚
â”‚ [Next: Advanced interventions â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Bleeding Assessment]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ Post-Endoscopic Care (Node BB â†’ FF)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”¬ POST-ENDOSCOPIC MANAGEMENT           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š PPI therapy optimization[25]:        â”‚
â”‚ â€¢ **After successful hemostasis:**      â”‚
â”‚ â€¢ **High-dose PPI Ã— 72h continuous OR** â”‚
â”‚ â€¢ **Intermittent 40mg IV BID Ã— 3 days** â”‚
â”‚ â€¢ **Then PO BID Ã— 2 weeks**             â”‚
â”‚                                         â”‚
â”‚ ğŸ¦  H. pylori management:                â”‚
â”‚ â€¢ **Test all peptic ulcer patients**    â”‚
â”‚ â€¢ **Triple therapy if positive**        â”‚
â”‚ â€¢ **Clarithromycin/amoxicillin/PPI**    â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Rebleeding risk assessment:          â”‚
â”‚ â€¢ **High-risk stigmata:** Serial monitoringâ”‚
â”‚ â€¢ **Rockall score >8:** Consider ICU    â”‚
â”‚ â€¢ **Repeat endoscopy** if rebleeding    â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Medication reconciliation:           â”‚
â”‚ â€¢ **NSAIDs:** Discontinue permanently   â”‚
â”‚ â€¢ **Aspirin:** Resume per cardiac risk  â”‚
â”‚ â€¢ **PPIs:** Continue appropriate durationâ”‚
â”‚                                         â”‚
â”‚ [Next: Disposition planning â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Endoscopic Therapy]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5B â€“ ICU Variceal Monitoring (Node GG â†’ II)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ ICU VARICEAL BLEEDING MONITORING     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š Continuous monitoring parameters:    â”‚
â”‚ â€¢ **Hemodynamic status:** MAP >65 mmHg  â”‚
â”‚ â€¢ **Hemoglobin levels:** Q4-6h initiallyâ”‚
â”‚ â€¢ **Mental status:** Hepatic encephalopathy screeningâ”‚
â”‚ â€¢ **Fluid balance:** Avoid over-resuscitationâ”‚
â”‚                                         â”‚
â”‚ ğŸ’Š 72-hour protocol continuation:       â”‚
â”‚ â€¢ **Octreotide 50mcg/hr Ã— 72h**         â”‚
â”‚ â€¢ **Ceftriaxone 1g daily Ã— 7 days**     â”‚
â”‚ â€¢ **PPI standard dose** (not high-dose) â”‚
â”‚                                         â”‚
â”‚ ğŸ§  Hepatic encephalopathy management:   â”‚
â”‚ â€¢ **Lactulose 30mL PO TID** if Grade â‰¥2 â”‚
â”‚ â€¢ **Rifaximin 550mg BID** as adjunct    â”‚
â”‚ â€¢ **Avoid sedating medications**        â”‚
â”‚                                         â”‚
â”‚ ğŸ“ˆ Success indicators:                  â”‚
â”‚ â€¢ **No rebleeding Ã— 72h**               â”‚
â”‚ â€¢ **Stable hemoglobin**                â”‚
â”‚ â€¢ **Improving liver function**          â”‚
â”‚                                         â”‚
â”‚ [Next: Step-down transition â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Bleeding Control]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6A â€“ Outpatient Management (Node K â†’ P)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ  LOW-RISK OUTPATIENT MANAGEMENT       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… Discharge criteria (all required)[46]:â”‚
â”‚ â€¢ **Oakland score â‰¤8** (for LGIB)       â”‚
â”‚ â€¢ **Glasgow-Blatchford 0-1** (for UGIB) â”‚
â”‚ â€¢ **Hemodynamically stable**            â”‚
â”‚ â€¢ **Minimal ongoing bleeding**          â”‚
â”‚ â€¢ **No high-risk comorbidities**        â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Discharge instructions:              â”‚
â”‚ â€¢ **Return for worsening bleeding**     â”‚
â”‚ â€¢ **Return for hemodynamic symptoms**   â”‚
â”‚ â€¢ **Medication modifications**          â”‚
â”‚ â€¢ **Dietary recommendations**           â”‚
â”‚                                         â”‚
â”‚ ğŸ“ Follow-up arrangements:              â”‚
â”‚ â€¢ **Primary care:** 24-48 hours        â”‚
â”‚ â€¢ **GI specialist:** 1-2 weeks         â”‚
â”‚ â€¢ **Outpatient endoscopy** if indicated â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Medication counseling:               â”‚
â”‚ â€¢ **Avoid NSAIDs** indefinitely        â”‚
â”‚ â€¢ **PPI if indicated** for ulcer prophylaxisâ”‚
â”‚ â€¢ **Iron supplementation** if anemic    â”‚
â”‚                                         â”‚
â”‚ [Next: Primary care follow-up â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Risk Assessment]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6B â€“ Medication Reconciliation (Node KK â†’ MM)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’Š COMPREHENSIVE MEDICATION RECONCILIATIONâ”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš« Medications to discontinue:          â”‚
â”‚ â€¢ **NSAIDs:** Permanent discontinuation â”‚
â”‚ â€¢ **Primary prevention aspirin:** Consider stoppingâ”‚
â”‚ â€¢ **Unnecessary anticoagulation**       â”‚
â”‚                                         â”‚
â”‚ âœ… Medications to continue:             â”‚
â”‚ â€¢ **Secondary prevention aspirin:** Resume within 7 days[30]â”‚
â”‚ â€¢ **Essential anticoagulation:** Resume based on bleeding severityâ”‚
â”‚ â€¢ **PPIs:** Continue appropriate durationâ”‚
â”‚                                         â”‚
â”‚ ğŸ«€ Cardiology coordination:             â”‚
â”‚ â€¢ **Recent stents:** Joint decision makingâ”‚
â”‚ â€¢ **High cardiac risk:** Early resumptionâ”‚
â”‚ â€¢ **Dual antiplatelet:** Specialist guidanceâ”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Resumption timeline:                 â”‚
â”‚ â€¢ **Aspirin:** Within 3-7 days if stableâ”‚
â”‚ â€¢ **Anticoagulation:** 7-15 days based on riskâ”‚
â”‚ â€¢ **P2Y12 inhibitors:** Case-by-case   â”‚
â”‚                                         â”‚
â”‚ ğŸ“š Patient education:                   â”‚
â”‚ â€¢ **Medication adherence importance**   â”‚
â”‚ â€¢ **Signs of rebleeding**               â”‚
â”‚ â€¢ **When to seek emergency care**       â”‚
â”‚                                         â”‚
â”‚ [Next: Discharge planning â–¶]           â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Recovery Care]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7 â€“ Final Disposition & Quality Metrics (Node MM - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ FINAL DISPOSITION & QUALITY TRACKING â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“ Disposition pathways:                â”‚
â”‚ â€¢ **Home:** Low-risk, stable patients   â”‚
â”‚ â€¢ **Medical floor:** Standard risk      â”‚
â”‚ â€¢ **Telemetry:** High-risk, need monitoringâ”‚
â”‚ â€¢ **ICU:** Hemodynamic instability      â”‚
â”‚ â€¢ **OR:** Emergency surgical interventionâ”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Quality metrics (2024 standards):    â”‚
â”‚ â€¢ **Time to risk stratification:** <60 minâ”‚
â”‚ â€¢ **Appropriate CTA utilization:** Based on hemodynamic statusâ”‚
â”‚ â€¢ **IR consultation time:** <90 min for positive CTAâ”‚
â”‚ â€¢ **Endoscopy timing:** Per risk level  â”‚
â”‚ â€¢ **30-day rebleeding rate:** <15%      â”‚
â”‚                                         â”‚
â”‚ ğŸ“ Follow-up coordination:              â”‚
â”‚ â€¢ **GI specialist:** All patients requiring interventionâ”‚
â”‚ â€¢ **Primary care:** Within 1 week       â”‚
â”‚ â€¢ **Hematology:** If underlying bleeding disorderâ”‚
â”‚ â€¢ **Cardiology:** If anticoagulation issuesâ”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Outcome tracking:                    â”‚
â”‚ â€¢ **Hemoglobin response to transfusion**â”‚
â”‚ â€¢ **Length of stay optimization**       â”‚
â”‚ â€¢ **Readmission prevention**            â”‚
â”‚ â€¢ **Patient satisfaction scores**       â”‚
â”‚                                         â”‚
â”‚ ğŸ“š Patient education completion:         â”‚
â”‚ â€¢ **Medication safety understanding**   â”‚
â”‚ â€¢ **Bleeding precautions awareness**    â”‚
â”‚ â€¢ **Emergency care decision-making**    â”‚
â”‚                                         â”‚
â”‚ âœ… GI BLEEDING PROTOCOL COMPLETE       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: All Treatment Pathways]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES GI BLEEDING ADDENDA

### **Enhanced RRT Response Program:**
- **Rapid Response Team:** Immediate access to gastroenterology, interventional radiology, and critical care
- **Point-of-Care Testing:** Hemoglobin monitoring with 15-minute turnaround
- **Blood Bank Integration:** Massive transfusion protocol with 1:1:1 ratios
- **Quality Metrics:** Evidence-based risk stratification compliance, time-to-intervention tracking

### **2023-2024 Evidence Integration:**
**ACG 2023 Lower GI Bleeding Guidelines[27][46]:**
- **Oakland score implementation:** â‰¤8 for safe discharge consideration
- **CT angiography emphasis:** First-line for hemodynamically significant hematochezia
- **Non-urgent colonoscopy preferred:** No outcome benefit from urgent approach
- **Enhanced anticoagulation reversal:** Specific agents for life-threatening bleeding

**2021 ACG Upper GI Bleeding Updates[25][26]:**
- **Hemoglobin threshold 7 g/dL:** For stable patients without CAD
- **Pre-endoscopic PPI therapy:** Recommended for all suspected PUD
- **Erythromycin prokinetic:** 250mg IV before delayed endoscopy

### **Advanced Risk Stratification Tools:**
**Glasgow-Blatchford Score (Validated 2024):**
- **Score 0-1:** Very low risk, consider discharge[25]
- **Score 2-6:** Low-moderate risk, inpatient observation
- **Score â‰¥7:** High risk, urgent intervention needed
- **Components:** BUN, Hemoglobin, BP, HR, melena, syncope

**Oakland Score (LGIB-Specific)[29]:**
- **Most discriminative for safe discharge**[29]
- **Score â‰¤8:** 95% probability safe discharge
- **Sensitivity 98%, Specificity 16%** for safe discharge
- **Components:** Age, sex, BP, HR, Hgb, bleeding history

### **Technology Integration (2024 Standards):**
**CT Angiography Protocol Enhancement:**
- **Multidetector CT:** 0.3-0.5 mL/min bleeding detection
- **85% sensitivity, 92% specificity** for active bleeding[27]
- **Rapid acquisition:** <5 minutes scanning time
- **Immediate IR notification** for positive studies

**Point-of-Care Ultrasound:**
- **Gastric distension assessment:** Volume estimation
- **IVC evaluation:** Volume status determination
- **Portal vein assessment:** For suspected portal hypertension

### **Interventional Radiology Integration:**
**Embolization Outcomes (2023 Data)[47]:**
- **Initial success rate:** 89-98%
- **Clinical success rate:** 70-80%
- **Complication rate:** 4.6% (mostly bowel infarction)
- **Rebleeding rate:** 10-25% within 30 days

**Superselective Technique Benefits:**
- **Reduced ischemic complications**
- **Higher success rates**
- **Preservation of collateral circulation**
- **Coil placement optimization**

### **Blood Product Management (Updated 2024):**
**Transfusion Thresholds:**
- **Hemoglobin <7 g/dL:** Standard threshold for stable patients[25]
- **Hemoglobin <8 g/dL:** For patients with CAD
- **Active bleeding:** Consider higher thresholds (8-9 g/dL)
- **Massive bleeding:** 1:1:1 ratio (RBC:FFP:Platelets)

**Platelet Management:**
- **Severe LGIB:** Maintain >50,000/Î¼L[30]
- **Endoscopic procedures:** >50,000/Î¼L threshold
- **No benefit from platelet transfusion** for antiplatelet drugs

### **Anticoagulation Management (2023 Updates):**
**Resumption Guidelines:**
- **Aspirin (secondary prevention):** Resume within 7 days[30]
- **Anticoagulation:** Resume 7-15 days based on bleeding severity
- **Recent stents (<1 year):** Multidisciplinary approach required
- **Primary prevention medications:** Can be permanently discontinued

**Reversal Agent Availability:**
- **4-Factor PCC:** For warfarin, INR >2.5, life-threatening bleeding
- **Idarucizumab:** Specific dabigatran reversal
- **Andexanet alfa:** For factor Xa inhibitors
- **Target INR <1.4** within 30 minutes for urgent procedures

### **Quality Improvement Metrics (2024 Evidence):**
**Process Measures:**
- **Risk stratification completion:** >95% within 1 hour
- **Appropriate CT-A utilization:** Based on hemodynamic status
- **IR consultation time:** <90 minutes for positive CT-A
- **Endoscopy timing:** Urgent (<12h) only for high-risk features

**Outcome Measures:**
- **30-day mortality:** <5% for non-variceal bleeding
- **Rebleeding rates:** <15% within 30 days
- **Length of stay:** Average 3-5 days for uncomplicated cases
- **Readmission prevention:** <10% within 30 days

### **Variceal Bleeding Enhancements (2024 AASLD):**
**Pharmacologic Management:**
- **Octreotide superiority:** Over terlipressin in availability
- **72-hour duration optimal:** Reduces rebleeding risk
- **Antibiotic prophylaxis mandatory:** Ceftriaxone 1g daily Ã— 7 days
- **Avoid over-transfusion:** Target Hgb 7-9 g/dL

**TIPS Integration:**
- **Early TIPS (<72h):** For high-risk patients
- **Child-Pugh Class A/B:** Best candidates
- **Contraindications:** Severe hepatic encephalopathy
- **Success rates:** 90-95% bleeding control

### **Patient Safety & Technology:**
**Clinical Decision Support Systems:**
- **Automated risk scoring:** Integration with EMR
- **Drug interaction screening:** Real-time alerts
- **Bleeding risk calculators:** Personalized assessments
- **Quality dashboards:** Real-time metric tracking

**Communication Protocols:**
- **Critical result notification:** Automated lab alerts
- **Multidisciplinary rounds:** Daily team communication
- **Family updates:** Structured communication plans
- **Discharge coordination:** Seamless care transitions

### **Special Population Considerations:**
**Elderly Patients (>75 years):**
- **Higher baseline Hgb targets:** 8-9 g/dL due to comorbidities
- **Careful fluid management:** Avoid volume overload
- **Medication reconciliation:** Minimize polypharmacy
- **Functional status assessment:** Discharge planning consideration

**Cirrhotic Patients:**
- **Portal pressure considerations:** Avoid over-resuscitation
- **Infection prophylaxis:** Universal antibiotic coverage
- **MELD score integration:** Risk stratification
- **Multidisciplinary care:** Hepatology involvement

### **Cost-Effectiveness & Value-Based Care:**
**High-Value Interventions:**
- **Risk-based triage:** Prevents unnecessary admissions
- **CT-A for appropriate patients:** Guides targeted intervention
- **Non-urgent colonoscopy:** Equivalent outcomes, lower cost
- **Early discharge protocols:** Reduces length of stay

**Resource Optimization:**
- **Blood product stewardship:** Evidence-based thresholds
- **ICU bed utilization:** Appropriate risk-based triage
- **Specialist consultation timing:** Optimized workflows
- **Outpatient follow-up:** Prevents readmissions

## REFERENCE GUIDELINES
- **2023 American College of Gastroenterology Clinical Guidelines for Management of Patients with Acute Lower Gastrointestinal Bleeding**
- **2021 ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding**
- **2024 AASLD Practice Guidelines: Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis**
- **2024 ACG/SAR Consensus Statement: Role of Imaging for GI Bleeding**
- **Virtua Health System Gastrointestinal Bleeding Protocol v2025**

**This comprehensive protocol integrates the latest evidence-based GI bleeding management with advanced risk stratification tools, optimized anticoagulation management, enhanced interventional radiology integration, and technology-enabled quality improvement systems optimized for excellent patient outcomes at Virtua Voorhees.**
